With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
News & Analysis: Neurocrine Biosciences
Strong second-quarter results announced after the close Monday boosted market optimism about this small biotech.
Sales soared for the drug Ingrezza. And key pipeline developments are on the way.
NBIX earnings call for the period ending June 30, 2019.
NBIX earnings call for the period ending March 31, 2019.
A midsize acquisition seems imminent, and these two would fit like a glove.
NBIX earnings call for the period ending December 31, 2018.
The company just licensed four drug programs for a cool $165 million up-front payment -- with the potential to receive $1.7 billion in future milestone payments.
Earnings per share will more than double for each of these specialty drugmakers.
Find out which of these companies warned about its future results.